Lipid-Based Drug Delivery Nanoplatforms for Colorectal Cancer Therapy
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) is a prevalent disease worldwide, and patients at late stages of CRC often suffer from a high mortality rate after surgery. Adjuvant chemotherapeutics (ACs) have been extensively developed to improve the survival rate of such patients, but conventionally formulated ACs inevitably distribute toxic chemotherapeutic drugs to healthy organs and thus often trigger severe side effects. CRC cells may also develop drug resistance following repeat dosing of conventional ACs, limiting their effectiveness. Given these limitations, researchers have sought to use targeted drug delivery systems (DDSs), specifically the nanotechnology-based DDSs, to deliver the ACs. As lipid-based nanoplatforms have shown the potential to improve the efficacy and safety of various cytotoxic drugs (such as paclitaxel and vincristine) in the clinical treatment of gastric cancer and leukemia, the preclinical progress of lipid-based nanoplatforms has attracted increasing interest. The lipid-based nanoplatforms might be the most promising DDSs to succeed in entering a clinical trial for CRC treatment. This review will briefly examine the history of preclinical research on lipid-based nanoplatforms, summarize the current progress, and discuss the challenges and prospects of using such approaches in the treatment of CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 2×
“Stabilized nucleic acid-lipid particles (SNALPs), developed by Tekmira Pharmaceuticals, represent one such formulation [97,98].”
BackgroundNanoparticles in the clinic: an update
Anselmo, A. C., & Mitragotri, S. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10143 · Cited by 1,766
Plant-derived exosomal MicroRNAs shape the gut microbiota
Teng, Y., Ren, Y., Sayed, M., Hu, X., Lei, C., Kumar, A., Hutchins, E., Mu, J., Deng, Z., Luo, C., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.10.001 · Cited by 1,027
AJCC 8th Edition: Colorectal Cancer
Weiser, M. R. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6462-1 · Cited by 1,020 · cited 1×
“Although the survival rate of early-stage CRC patients is relatively high (above 50%, stages 0 to II-B), those diagnosed in advanced stages (for example stages IIIB–IVB) exhibit an extremely low survival rate (as low as 5%) even after surgical resection [15,16].”
BackgroundStrategic approaches for colon targeted drug delivery: an overview of recent advancements
Lee, S. H., Bajracharya, R., Min, J. Y., Han, J.-W., Park, B. J., & Han, H.-K. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12010068 · Cited by 318
Duan, X., Chan, C., Han, W., Guo, N., Weichselbaum, R. R., & Lin, W. (2019) · Nature Communications · doi:10.1038/s41467-019-09221-x · Cited by 256
Advances in colon-targeted nano-drug delivery systems: challenges and solutions
Naeem, M., Awan, U. A., Subhan, F., Cao, J., Hlaing, S. P., Lee, J., Im, E., Jung, Y., & Yoo, J.-W. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01219-0 · Cited by 248
The Roles of Cancer Stem Cells and Therapy Resistance in Colorectal Carcinoma
Das, P. K., Islam, F., & Lam, A. K. (2020) · Cells · doi:10.3390/cells9061392 · Cited by 210
A novel 5-Fluorouracil targeted delivery to colon cancer using folic acid conjugated liposomes
Handali, S., Moghimipour, E., Rezaei, M., Ramezani, Z., Kouchak, M., Amini, M., Angali, K. A., Saremy, S., & Dorkoosh, F. A. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.09.128 · Cited by 154
Cited by
Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment
Choukaife, H., Seyam, S., Alallam, B., Doolaanea, A. A., & Alfatama, M. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s375229 · Cited by 127
“CRC is divided into five phases by the American Joint Committee on Cancer, where the treatment strategy is highly related to the corresponding stage.(5) Stage 0 is characterised by the presence of abnormal colon cells or polyps on the mucosa when found early enough, and it is completely curable following a surgical re…”
BackgroundRecent updates on innovative approaches to overcome drug resistance for better outcomes in cancer
Sharma, M., Bakshi, A. K., Mittapelly, N., Gautam, S., Marwaha, D., Rai, N., Singh, N., Tiwari, P., Agarwal, N., Kumar, A., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.007 · Cited by 84
Sharma, S., Bhattacharya, S., Joshi, K., & Singh, S. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05331-8 · Cited by 13
Metadata
- Authors
- Yang, C., & Merlin, D.
- Venue
- Nanomaterials
- Publisher
- MDPI AG
- Published
- 2020-07-21
- Volume
- 10
- Issue
- 7
- Pages
- 1424
- ISSN
- 2079-4991 (ISSN-L)
- OpenAlex
- W3045441629
- Cited by
- 82
- References
- 13
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipid-Based Drug Delivery Nanoplatforms for Colorectal Cancer Therapy. https://app.cochat.ai/papers/10.3390/nano10071424
- The paper
- Yang, C., & Merlin, D. (2020). Lipid-Based Drug Delivery Nanoplatforms for Colorectal Cancer Therapy. Nanomaterials. https://doi.org/10.3390/nano10071424
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.